Tumor‑suppressive Effects of Smad‑ubiquitination Regulator 2 in Papillary Thyroid Carcinoma

Overview

Journal Oncol Lett

Specialty Oncology

Date 2024 Apr 22

PMID 38646500

Authors

Guirong Luo

Liting Zhang

Lihong Zhang

Wenyi Wu

Jianqing Lin

Haihong Shi

Yihuang Yu

Weigang Qiu

Jinyan Chen

Hansen Ding

Xinyao Chen

Affiliations

Soon will be listed here.

Abstract

Smad-ubiquitination regulator 2 (SMURF2) functions as a homolog of E6AP carboxyl terminus-type E3 ubiquitin ligase to regulate cell cycle progression and tumor growth factor expression. SMURF2 has been revealed to function as a tumor suppressor in a number of cancers; however, its function in papillary thyroid carcinoma (PTC) remains largely unknown. Therefore, the aim of the present study was to investigate the function of SMURF2 in PTC. Reverse transcription-quantitative PCR and western blotting were used to detect cellular expression of SMURF2 . After increasing or inhibiting the expression of SMURF2, MTT was used to detect the effect on tumor cell proliferation and Transwell assays were used to detect the effect on tumor cell migration and invasion. Finally, ELISA was used to detect the effects on glucose and glutamine metabolism in tumor cells and the findings revealed that SMURF2 was downregulated in PTC tissues. Moreover, SMURF2 inhibited the proliferation, invasion and migration of PTC cells, and promoted their apoptosis. Finally, SMURF2 inhibited cell glycolysis and glutaminolysis and affected metabolism in the PTC cell line, TPC-1. Thus, the findings of the present study suggest that SMURF2 may be a potential target in the treatment of PTC.

References

Bedford L, Lowe J, Dick L, Mayer R, Brownell J . Ubiquitin-like protein conjugation and the ubiquitin-proteasome system as drug targets. Nat Rev Drug Discov. 2010; 10(1):29-46. PMC: 7097807. DOI: 10.1038/nrd3321. View

Li Z, Zhang H . Reprogramming of glucose, fatty acid and amino acid metabolism for cancer progression. Cell Mol Life Sci. 2015; 73(2):377-92. PMC: 11108301. DOI: 10.1007/s00018-015-2070-4. View

Fan Q, Wang Q, Cai R, Yuan H, Xu M . The ubiquitin system: orchestrating cellular signals in non-small-cell lung cancer. Cell Mol Biol Lett. 2020; 25:1. PMC: 6966813. DOI: 10.1186/s11658-019-0193-6. View

Yu L, Dong L, Wang Y, Liu L, Long H, Li H . Reversible regulation of SATB1 ubiquitination by USP47 and SMURF2 mediates colon cancer cell proliferation and tumor progression. Cancer Lett. 2019; 448:40-51. DOI: 10.1016/j.canlet.2019.01.039. View

Blank M, Tang Y, Yamashita M, Burkett S, Cheng S, Zhang Y . A tumor suppressor function of Smurf2 associated with controlling chromatin landscape and genome stability through RNF20. Nat Med. 2012; 18(2):227-34. PMC: 3274650. DOI: 10.1038/nm.2596. View

Gao Q, Wang S, Zhang Z . E3 ubiquitin ligase SMURF2 prevents colorectal cancer by reducing the stability of the YY1 protein and inhibiting the SENP1/c-myc axis. Gene Ther. 2021; 30(1-2):51-63. DOI: 10.1038/s41434-021-00289-z. View

Cameselle-Teijeiro J . [Changes and Perspectives in the New 2022 WHO Classification of Thyroid Neoplasms]. Rev Esp Patol. 2022; 55(3):145-148. DOI: 10.1016/j.patol.2022.06.001. View

Livak K, Schmittgen T . Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 2002; 25(4):402-8. DOI: 10.1006/meth.2001.1262. View

Song D, Li S, Ning L, Zhang S, Cai Y . Smurf2 suppresses the metastasis of hepatocellular carcinoma via ubiquitin degradation of Smad2. Open Med (Wars). 2022; 17(1):384-396. PMC: 8874264. DOI: 10.1515/med-2022-0437. View

10.

Liu Y, Zhou Q, Song S, Tang S . Integrating metabolic reprogramming and metabolic imaging to predict breast cancer therapeutic responses. Trends Endocrinol Metab. 2021; 32(10):762-775. DOI: 10.1016/j.tem.2021.07.001. View

11.

Sun L, Suo C, Li S, Zhang H, Gao P . Metabolic reprogramming for cancer cells and their microenvironment: Beyond the Warburg Effect. Biochim Biophys Acta Rev Cancer. 2018; 1870(1):51-66. DOI: 10.1016/j.bbcan.2018.06.005. View

12.

Chaudhary K, Kinslow C, Cheng H, Silva J, Yu J, Wang T . Smurf2 inhibition enhances chemotherapy and radiation sensitivity in non-small-cell lung cancer. Sci Rep. 2022; 12(1):10140. PMC: 9203496. DOI: 10.1038/s41598-022-14448-8. View

13.

Li Y, Yang D, Tian N, Zhang P, Zhu Y, Meng J . The ubiquitination ligase SMURF2 reduces aerobic glycolysis and colorectal cancer cell proliferation by promoting ChREBP ubiquitination and degradation. J Biol Chem. 2019; 294(40):14745-14756. PMC: 6779433. DOI: 10.1074/jbc.RA119.007508. View

14.

Lim H, Devesa S, Sosa J, Check D, Kitahara C . Trends in Thyroid Cancer Incidence and Mortality in the United States, 1974-2013. JAMA. 2017; 317(13):1338-1348. PMC: 8216772. DOI: 10.1001/jama.2017.2719. View

15.

Ilic N, Tao Y, Boutros-Suleiman S, Kadali V, Emanuelli A, Levy-Cohen G . SMURF2-mediated ubiquitin signaling plays an essential role in the regulation of PARP1 PARylating activity, molecular interactions, and functions in mammalian cells. FASEB J. 2021; 35(4):e21436. DOI: 10.1096/fj.202001759R. View

16.

Tan Y, Chen Y, Du M, Peng Z, Xie P . USF2 inhibits the transcriptional activity of Smurf1 and Smurf2 to promote breast cancer tumorigenesis. Cell Signal. 2018; 53:49-58. DOI: 10.1016/j.cellsig.2018.09.013. View

17.

Coelho R, Fortunato R, Carvalho D . Metabolic Reprogramming in Thyroid Carcinoma. Front Oncol. 2018; 8:82. PMC: 5876306. DOI: 10.3389/fonc.2018.00082. View

18.

Sun T, Liu Z, Yang Q . The role of ubiquitination and deubiquitination in cancer metabolism. Mol Cancer. 2020; 19(1):146. PMC: 7529510. DOI: 10.1186/s12943-020-01262-x. View

19.

Pu W, Shi X, Yu P, Zhang M, Liu Z, Tan L . Single-cell transcriptomic analysis of the tumor ecosystems underlying initiation and progression of papillary thyroid carcinoma. Nat Commun. 2021; 12(1):6058. PMC: 8523550. DOI: 10.1038/s41467-021-26343-3. View